At QurAlis, we are pioneering the path to conquering ALS and other neurodegenerative diseases with genetically validated targets with next-generation precision medicines. Our proprietary platforms and unique biomarkers enable the design and development of precision medicines that act directly on disease-causing genetic alterations.
We are advancing a deep pipeline of antisense oligonucleotides (ASOs) and small molecule programs addressing sub-forms of ALS that account for the majority of ALS patients. And, we are leveraging our insights, platforms, and successes in ALS to collaborate and expand our pipeline to other neurodegenerative diseases, such as frontotemporal-degeneration (FTD).
Our goal is to halt disease progression and significantly improve outcomes.
Our mission is to make a meaningful difference in patients’ lives.
That is QurAlis.